The Director General of the Agence nationale de sécurité du médicament et des produits de santé may suspend or withdraw a compassionate access authorisation if the conditions laid down in I, II and V of Article L. 5121-12-1 or the provisions of this section are not complied with, or for any other public health reason.
Except in cases of urgency, suspension or withdrawal may only take place after the authorisation holder has been invited to submit its observations.
Decisions to suspend or withdraw authorisations must state the reasons on which they are based and indicate the appeal procedures and deadlines.
The period of suspension may not exceed three months.